Ophthalmology.
Ophthalmology
Macular Degeneration
The number of people living with macular degeneration is similar to that of those who have been diagnosed with all types of invasive cancers.
DNX is developing a long-acting version (DNX-214) of a current available treatment that has the potential of reducing the intra-ocular injection frequency and thereby reducing the treatment cost and clinical burden.
Reference Resources
*BrightFocus Foundation. Retrieved Jun. 2015 from http://www.brightfocus.org/
*Macular Society. Retrieved Jun. 2015 from http://www.macularsociety.org/
*Seeing Beyond Vision Loss. Retrieved Jun. 2015 from http://www.cnib.ca/